Key facts
General Oncology, Inc.
New Form D on file · 2026-04-23 · the record
What the record says
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $4.81M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Use of proceeds, as written on the filing
Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees or to related entities to those listed in Item 3.
Company officers on record
Jeffrey Glazier is named as Executive Officer and Director on the Form D that General Oncology, Inc. filed with the SEC on 23 April 2026, one of 5 people that filing names.
Arnold Glazier is named as Executive Officer and Director on the Form D that General Oncology, Inc. filed with the SEC on 23 April 2026, one of 5 people that filing names.
Abid Ansari is named as Executive Officer on the Form D that General Oncology, Inc. filed with the SEC on 23 April 2026, one of 5 people that filing names.
Michael Petit is named as Director on the Form D that General Oncology, Inc. filed with the SEC on 23 April 2026, one of 5 people that filing names.
Barry Seeman is named as Director on the Form D that General Oncology, Inc. filed with the SEC on 23 April 2026, one of 5 people that filing names.
5 people named on the filing — 3 holding an executive role and 2 as directors only.
Named as of the 2026-04-23 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
- 5 people named on the filing — 3 holding an executive role and 2 as directors only.
No investor is drawn from a Form D — the form states how many invested and never who.
Want the whole picture on General Oncology, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on General Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on General Oncology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The full profile
Source Check, INVEST, RECRUIT and Press Requests on General Oncology, Inc.
- Source Check — verify Jeffrey Aaron Glazier's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Jeffrey Aaron Glazier for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist General Oncology, Inc.You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind General Oncology, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.